← Back to Search

Community Health Navigator Program for Chronic Conditions

N/A
Waitlist Available
Led By Kerry A McBrien, MD, MPH
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Poorly controlled diabetes (A1C > 9% on at least one occasion within the past year or labile)
Stage 3b or greater chronic kidney disease (estimated glomerular filtration rate < 45 mL/min/1.73m2 in past year)
Must not have
Patient unable to provide informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 36 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a program that uses community health navigators to help patients with multiple long-term health conditions get the care and resources they need.

Who is the study for?
This trial is for individuals with poorly controlled high blood pressure or diabetes, advanced kidney disease, heart failure, COPD or asthma with frequent visits, and ischemic heart disease. It's not suitable for those who can't consent, are in long-term care facilities, or if their health provider advises against it.
What is being tested?
The ENCOMPASS study tests a Community Health Navigator Program where trained community members help patients manage multiple chronic conditions by guiding them through the healthcare system and connecting them to resources in Alberta, Canada.
What are the potential side effects?
Since this intervention involves guidance and support rather than medical treatment, traditional side effects like you'd see with medications aren't expected. However, there may be indirect effects based on individual experiences with the program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My diabetes is not well-managed, with an A1C over 9% in the past year.
Select...
My kidney function is reduced, with a filtration rate below 45 mL/min.
Select...
I have been diagnosed with heart disease.
Select...
I have been diagnosed with congestive heart failure.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unable to understand and give consent for treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acute care service use
Secondary study objectives
Acute care costs
All-cause mortality rate
Anxiety symptoms
+22 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Community health navigator program for six months
Group II: ControlExperimental Treatment1 Intervention
Waitlist control: six-month waiting period followed by six months of community health navigator program
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Community Health Navigator Program
2021
N/A
~340

Find a Location

Who is running the clinical trial?

University of AlbertaOTHER
920 Previous Clinical Trials
431,720 Total Patients Enrolled
12 Trials studying Coronary Artery Disease
19,284 Patients Enrolled for Coronary Artery Disease
University of CalgaryLead Sponsor
806 Previous Clinical Trials
883,855 Total Patients Enrolled
11 Trials studying Coronary Artery Disease
10,735 Patients Enrolled for Coronary Artery Disease
Kerry A McBrien, MD, MPHPrincipal InvestigatorUniversity of Calgary
3 Previous Clinical Trials
455 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
455 Patients Enrolled for Coronary Artery Disease

Media Library

Community Health Navigator Program Clinical Trial Eligibility Overview. Trial Name: NCT04791267 — N/A
Coronary Artery Disease Research Study Groups: Intervention, Control
Coronary Artery Disease Clinical Trial 2023: Community Health Navigator Program Highlights & Side Effects. Trial Name: NCT04791267 — N/A
Community Health Navigator Program 2023 Treatment Timeline for Medical Study. Trial Name: NCT04791267 — N/A
~15 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top